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LETTER TO THE EDITOR
Pathotypes and probiotics: response to a 
commentary on the detection of a Shiga toxin 




A recent report on the detection in a Crohn’s disease (CD) patient of an adherent and invasive Shiga toxin producing 
Escherichia coli (STEC) (Gut pathogens 2015, 7:2) prompted a commentary expressing some skepticism on the signifi‑
cance of the paper findings (Gut pathogens 2015, 7:15). Besides focusing on recurrent issues concerning the difficul‑
ties in defining a pathogen, the opinion considers recent data demonstrating the presence of virulence factors in a 
commercial probiotic. In response to the commentary’s observations, additional information on the described STEC 
strain, as well as a short discussion on CD associated E. coli are presented here.
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Letter to the editor
The commentary by Wassenaar and Gunzer [1] on a 
recently published characterization study of a Crohn’s dis-
ease (CD) Escherichia coli combining virulence proper-
ties of multiple pathotypes [2] hits the complex issue on 
how to identify a pathogenic strain within this species, 
because of its high genetic and phenotypic heterogeneity 
and varying potential to cause disease. E. coli is a resident 
member of gut microbiota and a multi-disease organism 
alike, including a predominantly commensal and a smaller 
group of pathogenic strains [3]. The observation of a high 
numbers of E. coli in the gut of inflammatory bowel dis-
eases (IBD) patients by many independent researchers in 
the last decades [4–6] has made these bacteria suspicious 
of involvement with these diseases as well. The main point 
expressed in the commentary is that the presence of viru-
lence genes in an E. coli strain is not sufficient to grant it a 
role in disease because it has been found that pathogenic 
and probiotic strains of long recorded history of safe use 
share virulence genes and the administration of the later 
in a high dose to volunteers had no detrimental effects [7]. 
These findings are really important since they can instigate 
a discussion towards a better discernment of what among 
the many known E. coli traits can be considered as true 
virulence factors. Yet, in my view the data are still modest 
to sustain any conclusion and care must be taken to avoid 
generalizations. The number of virulence genes detected 
in the probiotics was limited and in general restricted to 
factors involved in colonization and fitness (toxins genes, 
for example, were not found). The comparison of EDL933 
strain’s proteome with that of G3/10, one of the probiotic 
strain used in the study, showed that the protein genes typ-
ical of the former were mostly absent in the probiotic E. 
coli [7]. Analysis of genetic relationship put probiotics and 
commensal or non-pathogenic strains in a single cluster 
apart from E. coli reference pathogenic strains.
The commentary on da Silva Santos et al.’s paper seems 
not to consider that the focus of the original work was not 
restricted to investigate genetic traits, but also virulence 
associated phenotypes, notably the capacity to adhere and 
to invade epithelial cells. E. coli D92/09 strain was able 
to replicate inside macrophages and its efficiency of entry 
into these cells was higher than that shown by adherent 
and invasive E. coli (AIEC) strain LF82 [2]. Innumerous 
studies published to date [5, 8, 9] have demonstrated a 
Open Access
*Correspondence:  josias@ibb.unesp.br 
Laboratory of Medical Bacteriology, Department of Microbiology 
and Immunology, Institute of Biosciences of the State University of São 
Paulo (UNESP), Distrito de Rubião Junior, Botucatu, SP CEP 18618‑970, 
Brazil
Page 2 of 3Rodrigues.  Gut Pathog  (2015) 7:17 
high prevalence of adherent strains among E. coli from 
CD patients. The characterization of the invasive phe-
notype of a strain from one of these works [10] and sub-
sequent studies [11] led to the description of the AIEC 
pathotype. Evidence gathered from these studies settled 
the basis for the recognition of AIEC as the most prob-
able bacterial agent suspected of playing an active role 
in CD [12]. Concerning the strain described by da Silva 
Santos et  al. [2], in addition to the adherent and inva-
sive phenotype, the bacteria proved to be lethal to the 
host cell. This and other features reveal a virulence pro-
file distinct from those expressed by AIEC (Table 1) and 
whose significance should be investigated in experiments 
with animal models. In addition, search for strains bear-
ing markers similar to those observed in E. coli D92/09 
in other CD patients should be done. In a recent PCR 
screening [13, 14] performed in my lab to detect some 
E. coli O serogroups in a bacterial collection from nine 
CD patients and eight control subjects, who routinely 
attended the São Paulo State University Hospital (HC-
UNESP), a high prevalence of O25, O83 and O126 could 
be observed in both groups. One of these O25 strains, 
detected in a CD patient, belonged to the O25:H4 sero-
type and ST131, an ESBL producing virulent clone of 
global distribution [15, 16]. Strains of this clone bearing 
AIEC phenotype have been identified among both intes-
tinal and extraintestinal pathogenic E. coli (ExPEC) [17]. 
O25 and O83, but not O126, include multidrug resistant 
serotypes frequently associated with nosocomial infec-
tions [18]. D92/09 strain belongs to O126:H27 (Table 1), 
an O:H type traditionally involved with diarrheal dis-
eases [19], but which in this case marked a CD clinical 
isolate. Manual search in this strain’s genome revealed 
genes conferring resistance to aminoglycoside (strB), 
beta-lactam (blaTEM-1B), fluoroquinolone (QnrB19), tet-
racycline (tet(A)) and trimethoprim (dfrA8). This finding 
allied to the high prevalence of O126 strains among the 
patients, as mentioned above, could indicate that possibly 
strains within this serogroup can be involved with noso-
comial infections in HC-UNESP and that D92/09 strain 
may have infected the patient in the hospital environ-
ment. Since many CD E. coli strains belong to serotypes 
of ExPEC [17], some of which associated with nosoco-
mial infections, it is likely that by attending the hospital 
in a routine basis, it is reasonable to suppose that at least 
some of the CD patients may acquire infections by these 
bacteria in the hospital settings.
A significant consideration in the commentary refers to 
the absence of symptoms in the infected patient, a condi-
tion which was explained by the existence of an immune 
system control, preventing bacterial action [7]. Indeed, 
this might have been the case but not necessarily is to 
mean that the strain is devoid of any virulence potential. 
It has been shown that the abundance of E. coli in the 
ileal mucosa of post-operative CD patients may not be 
linked to disease activity [4, 5]. Nonetheless, the D92/09 
host presented discrete clinical activity at the site of bac-
terial isolation insufficient to produce detectable symp-
toms [2].
Concerning the involvement in CD, doubts remain 
not only in regard to D92/09 strain but also to E. coli as 
a whole. Many of the disease provoked by this species 
are attributable to opportunists sharing colonization fac-
tors of pathogenic strains. Abnormal proliferation and 
involvement with disease could depend on additional and 
particular bacterial properties which could act in specific 
predisposing condition of the host. That seems to be the 
case of CD patients whose ileal enterocytes overexpress 
carcinoembryonic antigen-related cell adhesion molecule 
6 (CEACAM6) which was shown to be a receptor for 
AIEC type 1 pili [20]. In theory, this predisposing con-
dition would also favor strains of the probiotics such as 
Symbioflor2, possessing type 1 pili. A number of key fac-
tors described in LF82 strain, not present in the probi-
otics, such as the ability to replicate inside macrophages 
and potential to form granulomas constitute evidence 
strong enough to suspect of the participation of AIEC 
in a disease with the clinical and histopathological fea-
tures typical of CD. In other words, the manifestation of 
virulence depends on the concerted action of multiple 
Table 1 Some features of E. coli D92/09 strain in comparison with AIEC LF82
a No other epithelial cell type was tested.
Feature D92/09 LF82
Origin Ileal biopsy and stool from an Ileal resected adult female CD patient [2] Ileal biopsy from an Ileal resected adult female CD patient [5]
Cell interaction Aggregative adhesion to cultured epithelial cells; invasion in Hep‑2  
and Caco‑2 cellsa; high invasive ability with discrete replication in  
macrophage J774; invasiveness associated with cytotoxic effect [2]
Diffuse adhesion to cultured epithelial cells [5]; invasion in 
several cell types, such as HEp‑2 [10], Caco‑2 and Int‑407 
[5]; invasion and replication in macrophage J774 [21]; do 
not kill host cells [10]
Typing Serotype O126:H27; EcoR phylogroup B2; ST 3057 [2] Serotype O83:H1; EcoR phylogroup B2 [22]; ST135 [17]
Genome size 4.94 Mbp [2] 4.88 Mbp [23]
Pathotype STEC AIEC
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factors. Although not fully characterized, the available 
information on D92/09 strain, configures a profile with 
potential do cause damage in a condition of opportunism 
such as that in CD [2].
In conclusion, both the Wassenaar and Gunzer’s com-
mentary on D92/09 strain and the results of their recently 
published work on virulence genes in probiotics are very 
interesting and should represent a starting point on a dis-
cussion which may broaden our knowledge on the differ-
ent ways that E. coli interacts with humans, as probiotics, 
commensals or pathogens.
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